DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Filanesib is an investigational drug.
There have been 4 clinical trials for Filanesib. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2014.
The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and [disabled in preview]. The leading clinical trial sponsors are Array BioPharma, PETHEMA Foundation, and Celgene Corporation.
There are one hundred and thirty-eight US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Filanesib
|Pembrolizumab (MK-3475) in MM Patients With Residual Disease||Adknoma Health Research||Phase 2|
|Pembrolizumab (MK-3475) in MM Patients With Residual Disease||Merck Sharp & Dohme Corp.||Phase 2|
|Pembrolizumab (MK-3475) in MM Patients With Residual Disease||PETHEMA Foundation||Phase 2|
Top disease conditions for Filanesib
Top clinical trial sponsors for Filanesib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Filanesib||Get Started Free||Remote loading of sparingly water-soluble drugs into lipid vesicles||ZONEONE PHARMA, INC. (San Francisco, CA)||Get Started Free|
|Filanesib||Get Started Free||Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)||BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE)||Get Started Free|
|Filanesib||Get Started Free||Peptidomimetic macrocycles as modulators of MCL-1||AILERON THERAPEUTICS, INC. (Cambridge, MA)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Filanesib||Australia||AU2015301234||2034-08-04||Get Started Free|
|Filanesib||Canada||CA2962709||2034-08-04||Get Started Free|
|Filanesib||China||CN106999419||2034-08-04||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|